Lupin Ltd

Lupin Ltd

Lupin Ltd reported its Q1 FY2027 results, with sales increasing 33.3% YoY to INR 82,172 Mn, driven by robust growth across key markets and improved profitability. EBITDA margin expanded 210 bps YoY to 31.4%. The company received 6 ANDA approvals from the US FDA and launched 3 products in the US market.

Lupin Ltd

Lupin Ltd has announced its unaudited standalone and consolidated financial results for the quarter ended June 30, 2026. The company's revenue from operations stood at ₹71,719.0 crore, with a net profit of ₹27,146.0 crore. The results were reviewed by the Audit Committee and approved by the Board of Directors.

Lupin Ltd

Lupin Ltd approved unaudited standalone and consolidated financial results for the quarter ended June 30, 2026, with a net profit of ₹27,146.0 and earnings per share of ₹59.37.

Lupin Ltd

Lupin Ltd held its 44th Annual General Meeting (AGM) on August 4, 2026, through video conferencing, where all five proposed resolutions were passed with the required majority. The meeting was attended by 77 members, and the company's performance and key initiatives were discussed.

Lupin Ltd

Lupin Ltd held its 44th Annual General Meeting (AGM) on August 4, 2026, through video conferencing. All five proposed resolutions were passed with the required majority. The meeting was attended by 77 members, and the company secretary informed that the statutory auditors' report and secretarial auditors' report did not contain any qualification, observation, or adverse remark.

Lupin Ltd

Lupin Ltd has received approval from the US FDA for its Abbreviated New Drug Application for Diazepam Injection USP, 10 mg/2 mL (5 mg/mL), Single-Dose Prefilled Syringes, with estimated annual sales of USD 77.9 million in the U.S.

Lupin Ltd

Lupin Ltd has announced the US FDA approval and launch of Sugammadex Injection in the US market.

Lupin Ltd

Lupin Ltd has scheduled an earnings call for Q1 FY27 on August 07, 2026, at 16:30 hrs (IST).

Lupin Ltd

Lupin Ltd has scheduled a Board meeting on August 06, 2026, to consider and approve the unaudited standalone and consolidated financial results for the quarter ended June 30, 2026.

Lupin Ltd

Lupin Ltd's wholly owned subsidiary, Lupin Inc. U.S.A., has entered into a licensing agreement with Kaveri Therapeutics, Inc. U.S.A. to grant exclusive perpetual license for two oncology programs, LNP7457 (PRMT5) and LNP8701 (SOS1), in exchange for an 82.2% equity stake in Kaveri.

Lupin Ltd

Lupin Ltd's Nomination and Remuneration Committee granted 1,567,591 stock options under its Employees Stock Option Scheme 2025. The options have an exercise price of ₹2.00 per share and will vest over three years in equal annual installments after the first year, subject to performance conditions. Grantees can exercise vested options within eight years from the effective grant date of July 1, 2026. This initiative is a standard practice for employee retention and motivation.